[Form 4] PMV Pharmaceuticals, Inc Insider Trading Activity

Rhea-AI Filing Summary

PMV Pharmaceuticals, Inc. (PMVP) – Form 4 insider transaction

President & CEO David Henry Mack reported a sale of 58,411 common shares on 07/01/2025 at an average price of $1.0645 per share. The sale was executed under Rule S (open-market or private sale) and, according to the filing, was undertaken solely to cover tax obligations arising from the vesting of restricted stock units (Footnote 1).

After the transaction, Mack continues to own 536,133 shares directly. He also has indirect interests of 165,307 shares (Stinson 2021 Irrevocable Trust), 147,915 shares (Mack-Mulligan Revocable Trust) and 56,978 shares (Mack/Mulligan 2020 Irrevocable Descendants’ Trust), bringing his total reported beneficial position to 906,333 shares. No derivative securities were bought or sold, and there were no new options, warrants, or RSU transactions reported.

The sale represents roughly 10.9 % of Mack’s direct holdings and about 6.4 % of his total reported beneficial ownership. Because the disposition was for tax-withholding purposes, it does not necessarily signal a change in sentiment; nevertheless, investors often monitor any CEO share sales for potential insight into insider views of future prospects.

Positive

• CEO retains a large ownership stake of approximately 906,333 shares after the sale, maintaining alignment with shareholders.
• Sale purpose disclosed as tax-withholding from RSU vesting, suggesting it is administrative rather than sentiment-driven.

Negative

• Insider sale by the CEO can be perceived negatively, even if for tax reasons, and represents about 10.9 % of his direct holdings.

Insights

Equity Analyst

TL;DR: Small tax-related sale; CEO still retains ~900k shares—neutral signal.

The 58.4k-share disposition equals just over 6 % of David Mack’s aggregate ownership and was explicitly tied to RSU tax withholding. Such administrative sales are routine and generally carry limited informational value about future fundamentals. Importantly, Mack’s remaining stake exceeds 900k shares, aligning management with shareholder interests. The lack of accompanying derivative activity or multiple insiders selling supports a neutral impact assessment.

Corporate Governance Specialist

TL;DR: Transaction looks procedural; governance risk low.

The Form 4 cites tax obligations as the rationale, a standard practice permitted under company policies and Rule 10b5-1 protections. Mack continues to be both CEO and director, and the retained stake remains significant, preserving incentive alignment. No red flags such as pattern selling, option repricing, or simultaneous insider disposals appear. Consequently, I classify this filing as not materially impactful from a governance risk perspective.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mack David Henry

(Last) (First) (Middle)

C/O PMV PHARMACEUTICALS, INC.

400 ALEXANDER PARK DRIVE, SUITE 301

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PMV Pharmaceuticals, Inc. [ PMVP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2025		S		58,411(1)	D	$1.0645	536,133(2)	D
Common Stock								165,307	I	See footnote(3)
Common Stock								147,915	I	See footnote(4)
Common Stock								56,978	I	See footnote(5)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs.

2. Includes 15,528 shares acquired under the Issuer's Employee Stock Purchase Plan on May 15, 2025.

3. The shares are held of record by the Stinson 2021 Irrevocable Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.

4. The shares are held of record by the Mack-Mulligan Revocable Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.

5. The shares are held of record by the Mack/Mulligan 2020 Irrevocable Descendants' Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.

	/s/ Robert Ticktin, by power of attorney	07/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many PMVP shares did CEO David Henry Mack sell?

He sold 58,411 common shares on 07/01/2025.

At what price were the PMVP shares sold?

The average sale price was $1.0645 per share.

Why were the shares sold by the CEO of PMV Pharmaceuticals?

Footnote 1 states the shares were sold to cover tax obligations related to RSU vesting.

How many PMVP shares does the CEO own after the transaction?

He owns 536,133 shares directly and 906,333 shares in total, including indirect holdings.

Were any derivative securities involved in this Form 4 filing?

No. No options, warrants, or other derivatives were acquired or disposed of.

Does this insider sale significantly impact PMVP’s outlook?

Experts view the transaction as administrative and neutral, with minimal impact on the company’s fundamental outlook.